Immunogenicity of the influenza vaccination in patients with chronic obstructive pulmonary disease (COPD).

Princess Alexandra Hospital0 sites171 target enrollmentAugust 21, 2020

Overview

No summary available.

Registry

who.int

Start Date

August 21, 2020

End Date

August 30, 2017

Last Updated

5 years ago

Study Type

Observational

Sex

All

Sponsor

•Mild to very Severe COPD with a post bronchiodilater FEV1 less than 80% predicted FEV1 /FVC ratio less than 0\.7\. COPD patients will be stable with no COPD exacerbations or respiratory infections within the last 4 weeks.
•Healthy controls no prior or current symptoms of lung disease, MRC dyspnoea scale less than 2 and normal spirometry. And normal spirometry with an FEV1 and FVC within normal range.

•Invasive malignancy within the last 2 years.
•Renal impairment (eGFR less than 40ml/min).
•Acute febrile illness with fever greater than 38\.5 dC.
•Hypersensitivity to egg protein.
•Use of oral Prednisolone (or equivalent) greater than or equal to 10mg per day.
•Use of other systemic immunosuppressive therapy.
•Anaphylaxis following a previous dose of influenza vaccine.
•Anaphylaxis following a vaccine component (including eggs).
•History of Guilliane Barre within 6 weeks of a previous influenza vaccination
•Cardiac disease, diabetes mellitus and superficial non\- melanoma skin cancers WILL NOT be exclusion criteria provided these are stable and well controlled in the opinion of the investigator.